

## DOSING AND ADMINISTRATION GUIDE FOR ELAHERE THE FIRST AND ONLY FR $\alpha$ -TARGETED TREATMENT FOR PLATINUM-RESISTANT OVARIAN CANCER<sup>1</sup>

ELAHERE is indicated for the treatment of adult patients with folate receptor-alpha (FR $\alpha$ ) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.

### PROPHYLACTIC MEDICATIONS PRIOR TO INFUSION

Help reduce the incidence and severity of infusion-related reactions and emesis by following the ELAHERE premedication guidelines<sup>1</sup>

| Premedication prior to each ELAHERE infusion <sup>1</sup>  |                         |   |   |
|--|-------------------------|---|---|
| Premedication  | Route of administration | Examples (or equivalent)  | Administration time prior to ELAHERE infusion |
| Corticosteroid   | IV                      | Dexamethasone<br>10 mg  | At least<br>30 minutes<br>prior               |
| Antihistamine  | Oral or IV              | Diphenhydramine<br>25 mg to 50 mg   |   |
| Antipyretic  | Oral or IV              | Acetaminophen<br>325 mg to 650 mg   |   |
| Antiemetic   | Oral or IV              | 5-HT <sub>3</sub> serotonin receptor antagonist or appropriate alternatives | Before each dose and thereafter as needed     |
| Consider additional premedications including corticosteroids the day prior to ELAHERE administration for patients who experience infusion-related reactions. |                         |   |   |

ADC=antibody-drug conjugate; IV=intravenous.

#### SELECT IMPORTANT SAFETY INFORMATION

##### WARNING: OCULAR TOXICITY

- ELAHERE can cause severe ocular toxicities, including visual impairment, keratopathy, dry eye, photophobia, eye pain, and uveitis.
- Conduct an ophthalmic exam including visual acuity and slit lamp exam prior to initiation of ELAHERE, every other cycle for the first 8 cycles, and as clinically indicated.
- Administer prophylactic artificial tears and ophthalmic topical steroids.
- Withhold ELAHERE for ocular toxicities until improvement and resume at the same or reduced dose.
- Discontinue ELAHERE for Grade 4 ocular toxicities.

Please see additional Important Safety Information and accompanying [Full Prescribing Information](#), including Boxed WARNING.

## CALCULATING STARTING DOSE<sup>1\*</sup>

- The recommended dose of ELAHERE is **6 mg/kg AIBW administered once every 3 weeks (21-day cycle)**
- ELAHERE is an IV infusion and is administered until disease progression or unacceptable toxicity
- Dosing based on AIBW reduces exposure variability for patients who are either under- or overweight

**The total dose of ELAHERE is calculated based on each patient's AIBW using the following formula:**

$$\text{AIBW} = \text{IBW (kg)} + 0.4 \times \left( \text{actual weight (kg)} - \text{IBW (kg)} \right)$$

**Female IBW (kg) = (0.9 x height in cm) - 92**

AIBW is equivalent to adjusted body weight (AdjBW).

Ensure all weight measurements are recorded in kilogram (kg) units and height measurements are recorded in centimeters (cm) for ELAHERE dose calculations.

- In the MIRASOL clinical study, the mean AIBW was 59.1 kg<sup>2</sup>
- Based on an AIBW of 59.1 kg, the dose would be 355 mg per cycle (4 vials). One vial contains 100 mg of mirvetuximab soravtansine-gynx in 20 mL (5 mg/mL)<sup>1</sup>
- **Dose modifications may help manage treatment-related toxicities<sup>1</sup>**

## INSTRUCTIONS FOR PREPARATION<sup>1</sup>



Calculate the dose (mg) (based on the patient's AIBW), total volume (mL) of solution required, and the number of vials of ELAHERE needed. More than one vial will be needed for a full dose. ELAHERE is available in 100 mg/20 mL (5 mg/mL) single-dose vials



Gently swirl and inspect each vial prior to withdrawing the calculated dose volume of ELAHERE. **Do not shake** the vial



Remove the vials of ELAHERE from the refrigerator and allow to warm to room temperature



Using aseptic technique, withdraw the calculated dose volume of ELAHERE for subsequent dilution



Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. ELAHERE is a clear to slightly opalescent, colorless solution



ELAHERE contains no preservatives and is intended for single dose only. Discard any unused drug remaining in the vial

## ADMINISTRATION<sup>1</sup>



Administer ELAHERE as an IV infusion only, using a 0.2 or 0.22 µm polyethersulfone (PES) in-line filter. Do not substitute other membrane materials

<sup>1</sup>This was the dose calculation process used in the clinical trials.  
AIBW=adjusted ideal body weight; IBW=ideal body weight; IV=intravenous.

Please see **Full Prescribing Information, including Boxed WARNING.**



## ADMINISTRATION (CONT'D)<sup>1</sup>



Administer the first dose at the rate of 1 mg/min

- If well tolerated after 30 minutes, the infusion rate can be increased to 3 mg/min
- If well tolerated after 30 minutes, the infusion rate can be increased to 5 mg/min

If no infusion-related reactions occur with the previous dose, subsequent infusions should be started at the maximally tolerated rate and may be increased up to a maximum infusion rate of 5 mg/min, as tolerated



ELAHERE is a hazardous drug. Follow applicable special handling and disposal procedures



DO NOT mix ELAHERE with other drugs or IV fluids



DO NOT mix ELAHERE with normal saline (0.9% Sodium Chloride Injection)

## ADDITIONAL DOSING AND ADMINISTRATION INFORMATION<sup>1</sup>

### Dilution

- ELAHERE must be diluted prior to administration with 5% Dextrose Injection, USP to a final concentration of 1 mg/mL to 2 mg/mL
- ELAHERE is incompatible with 0.9% Sodium Chloride Injection. ELAHERE must not be mixed with any other drugs or IV fluids
- Determine the volume of 5% Dextrose Injection, USP required to achieve the final diluted drug concentration. Either remove excess 5% Dextrose Injection, USP from a prefilled IV bag, or add the calculated volume of 5% Dextrose Injection, USP to a sterile empty IV bag. Then add the calculated dose volume of ELAHERE to the IV bag
- Gently mix the diluted drug solution by slowly inverting the bag several times to assure uniform mixing.  
**Do not shake or agitate**
- If the diluted infusion solution is not used immediately, store solution either at ambient temperature [18 °C to 25 °C (64.4 °F to 77 °F)] for no more than 8 hours (including infusion time), or under refrigeration 2 °C to 8 °C (36 °F to 46 °F) for no more than 12 hours. If refrigerated, allow the infusion bag to reach room temperature prior to administration. After refrigeration, administer diluted infusion solutions within 8 hours (including infusion time)
- **Do not freeze** prepared infusion solution

### Administration

- Inspect the ELAHERE IV infusion bag visually for particulate matter and discoloration prior to administration
- Administer premedications prior to ELAHERE administration
- Administer ELAHERE as an IV infusion only, using a 0.2 or 0.22 µm polyethersulfone (PES) in-line filter. Do not substitute other membrane materials
- Following the infusion, flush the IV line with 5% Dextrose Injection, USP to ensure delivery of the full dose. **Do not use any other IV fluids for flushing**

IV=intravenous.

Please see [Full Prescribing Information](#), including **Boxed WARNING**.



## PROACTIVE MANAGEMENT OF OCULAR EVENTS

**Work with an eye care provider (optometrist or ophthalmologist) to manage ocular events that may occur**



Patients should receive a baseline ophthalmic exam from an eye care provider, including visual acuity and slit-lamp exam, prior to treatment initiation, and follow-up exams during every other cycle for the first 8 cycles and as clinically indicated<sup>1</sup>



Tell your patients to avoid use of contact lenses<sup>1</sup>



The use of ophthalmic topical steroids and preservative-free lubricating eye drops\* is recommended. The initial prescription and renewals of any corticosteroid medication should be made only after examination with a slit lamp. Administer 1 drop of ophthalmic topical steroid in each eye **6 times daily** starting the day prior to each infusion of ELAHERE until day 4; then administer 1 drop in each eye **4 times daily** on days 5–8 of each cycle of ELAHERE<sup>1-4</sup>



Administer lubricating eye drops at least **4 times daily** and as needed, waiting at least **10 minutes** after administration of the ophthalmic topical steroid<sup>1</sup>

### Ocular events were mostly Grade 1 or 2<sup>5,6†</sup>

- 56% of patients treated with ELAHERE had an ocular AE (n=122); of those who had an ocular AE, 14% were Grade  $\geq 3$  (n=30)<sup>6</sup>
- Of the patients treated with ELAHERE who had an ocular event (n=122), 51% had complete resolution and 42% had partial improvement.<sup>‡</sup> Of the remaining 7% who had no documented improvement, 5% were at Grade 1 and 2% were at Grade 2<sup>2,6</sup>
- 1.8% of patients treated with ELAHERE discontinued due to ocular-related events<sup>5</sup>
- Median time to onset of first ocular AE was 5.4 weeks (range: 0.1 to 68.6)<sup>5</sup>

## DOSE MODIFICATIONS<sup>1</sup>

Dose modifications may help manage treatment-related toxicities. Adjust the dose while maintaining a 3-week interval between doses.

### Recommended dose reduction schedule for adverse events

|                       | ELAHERE dose level                           |
|-----------------------|--|
| Starting dose         | 6 mg/kg AIBW q3w (21-day cycle)              |
| First dose reduction  | 5 mg/kg AIBW q3w (21-day cycle)              |
| Second dose reduction | 4 mg/kg AIBW q3w (21-day cycle) <sup>a</sup> |

<sup>a</sup>Permanently discontinue in patients who cannot tolerate 4 mg/kg AIBW.

\*Preservative-free is not a requirement for all patients. Lubricating eye drops without preservatives are recommended for patients with sensitive eyes.

<sup>†</sup>Data cutoff was March 6, 2023.<sup>5</sup>

<sup>‡</sup>Partial improvement was defined as improvement by  $\geq 1$  grade from the worst grade at last follow-up.<sup>6</sup> AE=adverse event; AIBW=adjusted ideal body weight; q3w=every 3 weeks.

Please see [Full Prescribing Information](#), including **Boxed WARNING**.



## DOSE MODIFICATIONS<sup>1</sup> (CONT'D)

| Recommended dose modification guidelines for adverse events |   |   |
|---|---|---|
| Adverse event   | Severity of adverse event <sup>a</sup>  | Dosage modification   |
| Keratitis/keratopathy                                       | Nonconfluent superficial keratitis  | Monitor   |
|   | Confluent superficial keratitis, a cornea epithelial defect, or 3-line or more loss in best corrected visual acuity | Withhold until improved or resolved, then maintain at same dose level or consider dose reduction  |
|   | Corneal ulcer or stromal opacity or best corrected distance visual acuity 20/200 or worse                           | Withhold until improved or resolved, then reduce by one dose level  |
|   | Corneal perforation   | Permanently discontinue   |
| Uveitis   | Grade 1: Rare cell in anterior chamber  | Monitor   |
|   | Grade 2: 1-2+ cell or flare in anterior chamber   | Withhold until Grade 1 or less, then maintain dose at same dose level   |
|   | Grade 3: 3+ cell or flare in anterior chamber   | Withhold until Grade 1 or less, then reduce dose by one dose level  |
|   | Grade 4: Hypopyon   | Permanently discontinue   |
| Pneumonitis   | Grade 1   | Monitor   |
|   | Grade 2   | Withhold until Grade 1 or less, then maintain at same dose level or consider dose reduction   |
|   | Grade 3 or 4  | Permanently discontinue   |
| Peripheral neuropathy                                       | Grade 2   | Withhold until Grade 1 or less, then reduce by one dose level   |
|   | Grade 3 or 4  | Permanently discontinue   |
| Infusion-related reactions/hypersensitivity                 | Grade 1   | Maintain infusion rate  |
|   | Grade 2   | <ul style="list-style-type: none"> <li>Interrupt infusion and administer supportive treatment</li> <li>After recovery from symptoms, resume the infusion at 50% of the previous rate, and if no further symptoms appear, increase rate as appropriate until infusion is completed</li> <li>Administer additional premedication for future cycles</li> </ul> |
|   | Grade 3 or 4  | <ul style="list-style-type: none"> <li>Immediately stop infusion and administer supportive treatment</li> <li>Advise patient to seek emergency treatment and immediately notify their healthcare provider if the infusion-related symptoms recur</li> <li>Permanently discontinue</li> </ul>  |
| Hematological   | Grade 3 or 4  | Withhold until Grade 1 or less, then resume at one lower dose level   |
| Other adverse events  | Grade 3   | Withhold until Grade 1 or less, then resume at one lower dose level   |
|   | Grade 4   | Permanently discontinue   |

<sup>a</sup>Unless otherwise specified, National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.

Please see [Full Prescribing Information](#), including **Boxed WARNING**.



# INDICATION AND IMPORTANT SAFETY INFORMATION

## INDICATION

ELAHERE is indicated for the treatment of adult patients with folate receptor-alpha (FR $\alpha$ ) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.

## IMPORTANT SAFETY INFORMATION

### WARNING: OCULAR TOXICITY

- **ELAHERE can cause severe ocular toxicities, including visual impairment, keratopathy, dry eye, photophobia, eye pain, and uveitis.**
- **Conduct an ophthalmic exam including visual acuity and slit lamp exam prior to initiation of ELAHERE, every other cycle for the first 8 cycles, and as clinically indicated.**
- **Administer prophylactic artificial tears and ophthalmic topical steroids.**
- **Withhold ELAHERE for ocular toxicities until improvement and resume at the same or reduced dose.**
- **Discontinue ELAHERE for Grade 4 ocular toxicities.**

## WARNINGS and PRECAUTIONS

### Ocular Disorders

ELAHERE can cause severe ocular adverse reactions, including visual impairment, keratopathy (corneal disorders), dry eye, photophobia, eye pain, and uveitis.

Ocular adverse reactions occurred in 59% of patients with ovarian cancer treated with ELAHERE. Eleven percent (11%) of patients experienced Grade 3 ocular adverse reactions, including blurred vision, keratopathy (corneal disorders), dry eye, cataract, photophobia, and eye pain; two patients (0.3%) experienced Grade 4 events (keratopathy and cataract). The most common ( $\geq 5\%$ ) ocular adverse reactions were blurred vision (48%), keratopathy (36%), dry eye (27%), cataract (16%), photophobia (14%), and eye pain (10%).

The median time to onset for first ocular adverse reaction was 5.1 weeks (range: 0.1 to 68.6). Of the patients who experienced ocular events, 53% had complete resolution; 38% had partial improvement (defined as a decrease in severity by one or more grades from the worst grade at last follow up). Ocular adverse reactions led to permanent discontinuation of ELAHERE in 1% of patients.

Premedication and use of lubricating and ophthalmic topical steroid eye drops during treatment with ELAHERE are recommended. Advise patients to avoid use of contact lenses during treatment with ELAHERE unless directed by a healthcare provider.

Refer patients to an eye care professional for an ophthalmic exam including visual acuity and slit lamp exam prior to treatment initiation, every other cycle for the first 8 cycles, and as clinically indicated. Promptly refer patients to an eye care professional for any new or worsening ocular signs and symptoms.

Monitor for ocular toxicity and withhold, reduce, or permanently discontinue ELAHERE based on severity and persistence of ocular adverse reactions.

### Pneumonitis

Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ELAHERE.

Pneumonitis occurred in 10% of patients treated with ELAHERE, including 1% with Grade 3 events and 1 patient (0.1%) with a Grade 4 event. One patient (0.1%) died due to respiratory failure in the setting of pneumonitis and lung metastases. One patient (0.1%) died due to respiratory failure of unknown etiology. Pneumonitis led to permanent discontinuation of ELAHERE in 3% of patients.

Monitor patients for pulmonary signs and symptoms of pneumonitis, which may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. Infectious, neoplastic, and other causes for such symptoms should be excluded through appropriate investigations. Withhold ELAHERE for patients who develop persistent or recurrent Grade 2 pneumonitis until symptoms resolve to  $\leq$  Grade 1 and consider dose reduction. Permanently discontinue ELAHERE in all patients with Grade 3 or 4 pneumonitis. Patients who are asymptomatic may continue dosing of ELAHERE with close monitoring.

**Please see additional Important Safety Information and accompanying [Full Prescribing Information](#), including Boxed WARNING.**



## IMPORTANT SAFETY INFORMATION (CONT'D)

### Peripheral Neuropathy (PN)

Peripheral neuropathy occurred in 36% of patients with ovarian cancer treated with ELAHERE across clinical trials; 3% of patients experienced Grade 3 peripheral neuropathy. Peripheral neuropathy adverse reactions included peripheral neuropathy (20%), peripheral sensory neuropathy (9%), paraesthesia (6%), neurotoxicity (3%), hypoaesthesia (1%), peripheral motor neuropathy (0.9%), polyneuropathy (0.3%), and peripheral sensorimotor neuropathy (0.1%). Monitor patients for signs and symptoms of neuropathy, such as paresthesia, tingling or a burning sensation, neuropathic pain, muscle weakness, or dysesthesia. For patients experiencing new or worsening PN, withhold dosage, dose reduce, or permanently discontinue ELAHERE based on the severity of PN.

### Embryo-Fetal Toxicity

Based on its mechanism of action, ELAHERE can cause embryo-fetal harm when administered to a pregnant woman because it contains a genotoxic compound (DM4) and affects actively dividing cells.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ELAHERE and for 7 months after the last dose.

### ADVERSE REACTIONS

The most common ( $\geq 20\%$ ) adverse reactions, including lab abnormalities, were increased aspartate aminotransferase, fatigue, increased alanine aminotransferase, blurred vision, nausea, increased alkaline phosphatase, diarrhea, abdominal pain, keratopathy, peripheral neuropathy, musculoskeletal pain, decreased lymphocytes, decreased platelets, decreased magnesium, decreased hemoglobin, dry eye, constipation, decreased leukocytes, vomiting, decreased albumin, decreased appetite, and decreased neutrophils.

### DRUG INTERACTIONS

DM4 is a CYP3A4 substrate. Closely monitor patients for adverse reactions with ELAHERE when used concomitantly with strong CYP3A4 inhibitors.

### USE IN SPECIAL POPULATIONS

#### Lactation

Advise women not to breastfeed during treatment with ELAHERE and for 1 month after the last dose.

#### Hepatic Impairment

Avoid use of ELAHERE in patients with moderate or severe hepatic impairment (total bilirubin  $>1.5$  ULN).

Please see additional Important Safety Information and accompanying [Full Prescribing Information](#), including Boxed WARNING.





**ELAHERE**<sup>®</sup>

mirvetuximab soravtansine-gynx  
injection 100 mg

Please see [Full Prescribing Information](#), including **Boxed WARNING**.

**References:** **1.** ELAHERE. Package insert. AbbVie; 2024. **2.** Data on File. AbbVie, Inc. **3.** Moore KN, Martin LP, Matulonis UA, et al. IMG853 (mirvetuximab soravtansine), a folate receptor alpha (FR $\alpha$ )-targeting antibody-drug conjugate (ADC): single agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 3–7, 2016; Chicago, IL. **4.** Moore KN, Martin LP, O'Malley DM, et al. Safety and activity of mirvetuximab soravtansine (IMG853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. *J Clin Oncol*. 2017;35(10):1112–1118. **5.** Moore KN, Angelergues A, Konecny GE, et al. Mirvetuximab soravtansine in FR $\alpha$ -positive, platinum-resistant ovarian cancer. *N Engl J Med*. 2023;389:2162–2174. **6.** Moore KN, Angelergues A, Konecny GE, et al. Mirvetuximab soravtansine in FR $\alpha$ -positive, platinum-resistant ovarian cancer. *N Engl J Med*. Supplemental Appendix. Published online December 7, 2023. doi:10.1056/NEJMoa2309169

abbvie

© 2025 AbbVie. All rights reserved. US-MIRV-2400316  
ELAHERE and its design are trademarks of ImmunoGen, Inc., an AbbVie company.